Tetraphase Pharmaceuticals (TTPH) Trading 7.9% Higher

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH)’s share price traded up 7.9% during trading on Monday . The company traded as high as $3.74 and last traded at $3.70. 790,292 shares were traded during mid-day trading, a decline of 40% from the average session volume of 1,309,761 shares. The stock had previously closed at $3.43.

A number of equities analysts recently commented on the stock. BMO Capital Markets cut shares of Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price on the stock. in a research report on Wednesday, February 14th. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, February 6th. Stifel Nicolaus decreased their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, February 14th. WBB Securities started coverage on shares of Tetraphase Pharmaceuticals in a research report on Thursday, February 22nd. They issued a “speculative buy” rating and a $6.00 price objective on the stock. Finally, SunTrust Banks restated a “buy” rating and issued a $10.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. Tetraphase Pharmaceuticals currently has an average rating of “Hold” and an average price target of $7.22.

The company has a market cap of $190.90 million, a price-to-earnings ratio of -1.44 and a beta of 2.59.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. The firm had revenue of $1.89 million for the quarter, compared to analyst estimates of $1.88 million. Tetraphase Pharmaceuticals had a negative net margin of 1,061.06% and a negative return on equity of 85.70%. analysts forecast that Tetraphase Pharmaceuticals Inc. will post -1.56 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in shares of Tetraphase Pharmaceuticals by 20.1% during the 3rd quarter. California State Teachers Retirement System now owns 80,471 shares of the biopharmaceutical company’s stock valued at $550,000 after purchasing an additional 13,451 shares in the last quarter. AXA boosted its stake in Tetraphase Pharmaceuticals by 7.1% during the fourth quarter. AXA now owns 216,337 shares of the biopharmaceutical company’s stock worth $1,363,000 after acquiring an additional 14,400 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in Tetraphase Pharmaceuticals by 3.1% during the first quarter. Candriam Luxembourg S.C.A. now owns 520,613 shares of the biopharmaceutical company’s stock worth $1,598,000 after acquiring an additional 15,613 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Tetraphase Pharmaceuticals by 12.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 243,869 shares of the biopharmaceutical company’s stock worth $1,537,000 after acquiring an additional 26,790 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in Tetraphase Pharmaceuticals during the fourth quarter worth about $210,000. 58.56% of the stock is currently owned by hedge funds and other institutional investors.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply